How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

22,184 results for

Pediatric Books

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V

Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dupilumab (atopische Dermatitis bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 November 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A19-75 Dupilumab (atopic dermatitis in adolescents) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-75 Version 1.0 Dupilumab (atopic dermatitis in adolescents) 28 November 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dupilumab (atopic dermatitis in adolescents) – Benefit assessment according to §35a Social Code Book V Commissioning

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

22. Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V

and legally binding. IQWiG Reports – Commission No. A18-58 Mepolizumab (asthma in adolescents and children aged 6 years and older) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-58 Version 1.0 Mepolizumab (asthma in adolescents and children aged 6 years and older) 20 December 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Mepolizumab (asthma (...) in adolescents and children aged 6 years and older) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 24 September 2018 Internal Commission No.: A18-58 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A18-58 Version 1.0 Mepolizumab (asthma

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

23. Ivacaftor (cystic fibrosis, 6 years and older, with gating mutations) - Benefit assessment according to §35a Social Code Book V

Ivacaftor (cystic fibrosis, 6 years and older, with gating mutations) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Ivacaftor (zystische Fibrose, ab 6 Jahre, non- G551D Gating-Mutation) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 November 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. IQWiG Reports – Commission No. A19-66 Ivacaftor (cystic fibrosis, 6 years and older, non-G551D gating mutation) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-66 Version 1.0 Ivacaftor (cystic fibrosis, 6 years and older, non-G551D gating mutation) 28 November 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ivacaftor

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

24. Brivaracetam (epilepsy) - Benefit assessment in accordance with §35a Social Code Book V

and legally binding. IQWiG Reports – Commission No. A18-48 Brivaracetam (epilepsy in children and adolescents) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-48 Version 1.0 Brivaracetam (epilepsy in children and adolescents) 30 October 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Brivaracetam (epilepsy in children and adolescents) – Benefit (...) assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 30 July 2018 Internal Commission No.: A18-48 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A18-48 Version 1.0 Brivaracetam (epilepsy in children and adolescents) 30 October 2018 Institute

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

25. Lenvatinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V

Lenvatinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Lenvatinib (hepatozelluläres Karzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.1; Status: 13 February 2019). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports – Commission No. A18-57 Lenvatinib (hepatocellular carcinoma) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-57 Version 1.1 Lenvatinib (hepatocellular carcinoma) 13 February 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Lenvatinib (hepatocellular carcinoma) – Benefit assessment according to §35a Social Code Book

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

26. Ivacaftor (cystic fibrosis, 2 years and older, with gating mutations) - Benefit assessment according to §35a Social Code Book V

, childpreschool, benefit assessment, NCT01705145, NCT01946412, NCT02742519, NCT00909532, NCT00909727 Extract of dossier assessment A19-67 Version 1.0 Ivacaftor (cystic fibrosis, 2 years and older, with gating mutations) 28 November 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of abbreviations v 2 Benefit assessment 1 2.1 Executive summary of the benefit assessment 1 2.2 Research question 4 2.3 Information retrieval and study (...) Plattform. 2015 [Accessed: 07.06.2019]. URL: http://apps.who.int/trialsearch. 15. Vertex Pharmaceuticals. A phase 3, 2-arm, roll-over study to evaluate the long-term safety and pharmacodynamics of ivacaftor treatment in pediatric subjects with cystic fibrosis and a CFTR gating mutation: study VX11-770-109; clinical study report [unpublished]. 2016. 16. Rosenfeld M, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS et al. An open-label extension study of ivacaftor in children with CF and a CFTR

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

27. Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V

Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dupilumab (Asthma) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 November 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. 19-74 Dupilumab (asthma) – Benefit (...) assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-74 Version 1.0 Dupilumab (asthma) 28 November 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dupilumab (asthma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 29 August 2019 Internal Commission No.: A19-74 Address of publisher

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

28. Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V

Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Ipilimumab (Melanom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 9 May 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-12 Ipilimumab (melanoma) – Benefit (...) assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-12 Version 1.0 Ipilimumab (melanoma) 9 May 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ipilimumab (melanoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 15 February 2018 Internal Commission No.: A18-12 Address of publisher

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

29. Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V

Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Lumacaftor/Ivacaftor (zystische Fibrose) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 April 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission (...) No. A18-08 Lumacaftor/ivacaftor (cystic fibrosis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-08 Version 1.0 Lumacaftor/ivacaftor (cystic fibrosis) 27 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Lumacaftor/ivacaftor (cystic fibrosis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

30. Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V

Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dupilumab (atopische Dermatitis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-63 (...) Dupilumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-63 Version 1.0 Dupilumab (atopic dermatitis) 27 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 1 December

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

31. Damoctocog alfa (haemophilia A) - Benefit assessment according to §35a Social Code Book V

Damoctocog alfa (haemophilia A) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Damoctocog alfa pegol (Hämophilie A) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 March 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-86 (...) Damoctocog alfa pegol (haemophilia A) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-86 Version 1.0 Damoctocog alfa pegol (haemophilia A) 27 March 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Damoctocog alfa pegol (haemophilia A) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

32. Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V

Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Emicizumab (Hämophilie A) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-26 Emicizumab (haemophilia (...) A) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-26 Version 1.0 Emicizumab (haemophilia A) 13 June 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Emicizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 18 March 2019 Internal Commission No.: A19-26

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

33. The Influence of Presentation Format of Story on Narrative Production in Chinese Children Learning English-as-a-Second-Language: A Comparison Between Graphic Novel, Illustration Book and Text. (Abstract)

The Influence of Presentation Format of Story on Narrative Production in Chinese Children Learning English-as-a-Second-Language: A Comparison Between Graphic Novel, Illustration Book and Text. Past studies have shown that multimodal presentation of story can improve story-retelling performance in the first language. The purpose of the present study was to investigate whether similar multimedia effects can be observed in second language learning and graphic novel reading. A total of 51 Chinese (...) elementary school children, aged 7-8, who were learning English as a second language were recruited. They were randomly assigned to one of the three experimental conditions that differed in the format of story presentation: English text, English text with pictorial illustrations or graphic novel. After reading the same story, the children retold the story in English. The narratives produced were then rated by two independent raters. The results of group comparison showed that children from the three

2019 Journal of psycholinguistic research

34. Best practice for managing outpatient bookings

Best practice for managing outpatient bookings 1 Rapid Literature Review Best practice for managing outpatient bookings Citation Fiona Clay, Corey Joseph & Angela Melder. 2018. Best practice for managing outpatient bookings: Evidence Review. Centre for Clinical Effectiveness, Monash Health, Melbourne, Australia. Contact CCE@monashhealth.org Background Transformation of care at Monash Health is an organisation-wide program of work aiming to improve the efficiency of delivery and operations (...) of outpatient service delivery. The purpose of this is to inform the potential redesign of specialist outpatient services. To achieve this objective the review covered the following areas: ? Overview of approaches to outpatient services ? Referral management ? Appointment scheduling and booking ? Alternatives to Outpatient Appointments ? Management of waiting times ? Failure to attend ? Implementing patient-focused booking ? Follow-up ? Barriers to appointment booking ? Patient experience with specialist

2019 Monash Health Evidence Reviews

35. Glycopyrronium bromide (sialorrhoea) - Benefit assessment according to §35a Social Code Book V

? Carolin Weigel ? Beate Wieseler Keywords: glycopyrrolate, sialorrhoea, child, adolescent, benefit assessment Extract of dossier assessment A18-22 Version 1.0 Glycopyrronium bromide (sialorrhoea) 27 June 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - Executive summary of the benefit assessment Background In accordance with §36a Social Code Book (SBG) V, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess (...) Glycopyrronium bromide (sialorrhoea) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Glycopyrroniumbromid (Sialorrhö) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 June 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

36. Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V

; cohort B: n = 10) and continued their treatment from before the start of the study. HAVEN 2 is a single-arm, multicentre approval study of emicizumab for paediatric patients. The study included children (< 12 years of age) and adolescents (12 to 17 years of age, < 40 kg body weight) previously treated with bypassing agents who had congenital haemophilia A and high-titre factor VIII inhibitors (= 5 BU) in their medical history (N = 63). The company states that the before-and-after comparisons (...) Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Emicizumab (Hämophilie A) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 June 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

37. Hydrocortisone (adrenal insufficiency) - Benefit assessment according to §35a Social Code Book V

Balg ? Gertrud Egger ? Tatjana Hermanns ? Katharina Hirsch ? Vjollcë Olluri ? Ulrike Seay ? Volker Vervölgyi Keywords: hydrocortisone, adrenal insufficiency, child, adolescent, benefit assessment Extract of dossier assessment A18-29 Version 1.0 Hydrocortisone (adrenal insufficiency in children) 10 August 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - Executive summary of the benefit assessment Background In accordance with §35a Social Code Book (SBG) V, the Federal Joint (...) authoritative and legally binding. IQWiG Reports – Commission No. A18-29 Hydrocortisone (adrenal insufficiency in children) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-29 Version 1.0 Hydrocortisone (adrenal insufficiency in children) 10 August 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Hydrocortisone (adrenal insufficiency in children

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

38. Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V

viral hepatitis C in children and adolescents: UK experience. Arch Dis Child 2014; 99(6): 505-510. 21. Bortolotti F, Indolfi G, Zancan L, Giacchino R, Verucchi G, Camma C et al. Management of chronic hepatitis C in childhood: the impact of therapy in the clinical practice during the first 2 decades. Dig Liver Dis 2011; 43(4): 325-329. 22. Jonas MM, Balistreri W, Gonzalez-Peralta RP, Haber B, Lobritto S, Mohan P et al. Pegylated interferon for chronic hepatitis C in children affects growth and body (...) therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008; 27(2): 142-148. 17. Sokal EM, Bourgois A, Stephenne X, Silveira T, Porta G, Gardovska D et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010; 52(6): 827-831. Extract of dossier assessment A17-55 Version 1.0 Sofosbuvir (chronic hepatitis C in adolescents) 11 January 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - 23 - 18. Wirth

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

39. Ledipasvir/sofosbuvir (hepatitis C) ? Benefit assessment according to §35a Social Code Book V

Ledipasvir/sofosbuvir (hepatitis C) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 November 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG (...) Reports – Commission No. A17-41 Ledipasvir/sofosbuvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-41 Version 1.0 Ledipasvir/sofosbuvir (chronic hepatitis C in adolescents) 13 November 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ledipasvir/sofosbuvir (chronic hepatitis C in adolescents) – Benefit

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

40. Pocket book of hospital care for children: Second edition

Pocket book of hospital care for children: Second edition WHO | Pocket book of hospital care for children: Second edition WHO Regional websites Access Maternal, newborn, child and adolescent health Menu Pocket book of hospital care for children: Second edition Guidelines for the management of common childhood illnesses Authors : World Health Organization Publication details Number of pages : 412 Publication date : 2013 Languages : English, French, Khmer, Marathi, Russian, Vietnamese ISBN : 978 (...) 92 4 154837 3 Downloads pdf 2.39Mb pdf 3.36Mb pdf, 4.83Mb pdf 4.04Mb pdf, 3Mb pdf, 7Mb Overview This is the second edition of the Pocket book of hospital care for children . It is for use by doctors, nurses and other health workers who are responsible for the care of young children at the first level referral hospitals. The Pocket Book is one of a series of documents and tools that support the Integrated Management of Childhood Illness (IMCI). It is an update of the 2005 edition, and presents up

2013 World Health Organisation Guidelines

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>